Literature DB >> 29473686

Alternative Th17 and CD4+ CD25+ FoxP3+ cell frequencies increase and correlate with worse cardiac function in Chagas cardiomyopathy.

M S Almeida1, V M B Lorena1,2, C de A Medeiros3, W O Junior2,3, M da G A M Cavalcanti2,3, S M Martins2,3, C N L de Morais1.   

Abstract

Immune homeostasis has been suggested to play an important role in the clinical evolution of chronic Chagas disease; however, the immunopathologic factors involved have not been fully elucidated. Therefore, our study aimed to analyse the frequency of CD4+ CD25+ FoxP3+ cells, classic Th17 cells, alternative Th17 cells and IL-17+ B cells from peripheral blood of chronic cardiac patients after in vitro stimulation with Trypanosoma cruzi soluble EPI antigen. Patients were selected and classified according to clinical evaluation of cardiac involvement: mild, B1 (CARD1) (n = 20) and severe, C (CARD2) (n = 11). Patients with the indeterminate form of CD were included as the control group A (IND) (n = 17). Blood samples were collected and cultured in the presence of EPI antigen. Cells frequency and median fluorescence intensity (MFI) were obtained by flow cytometry. Our results showed that only CD4+ CD25+ FoxP3+ , CD4+ CD25high FoxP3+ , CD4+ IL-17+ IFN-γ- and CD4+ IL-17+ IFN-γ+ cells are more frequent in patients with severe cardiac disease and correlate with worse global cardiac function. However, while indeterminate patients demonstrated a positive correlation between CD4+ CD25+ FoxP3+ and CD4+ IL-17+ IFN-γ- Th17 cells, this relationship was not observed in cardiac patients. IL-17 expression by Th17 cells and B cells correlated with disease progression. Altogether our results suggest that the clinical progression of Chagas cardiomyopathy involves worsening of inflammation and impairment of immunoregulatory mechanisms.
© 2018 The Foundation for the Scandinavian Journal of Immunology.

Entities:  

Keywords:  Chagas; Th17; Treg; cardiomyopathy; interleukin 17

Mesh:

Substances:

Year:  2018        PMID: 29473686     DOI: 10.1111/sji.12650

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  Interleukin-17 mediated immunity during infections with Trypanosoma cruzi and other protozoans.

Authors:  María Carolina Amezcua Vesely; Constanza Rodríguez; Adriana Gruppi; Eva Virginia Acosta Rodríguez
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-01-24       Impact factor: 5.187

2.  IL-10-Dependent and -Independent Mechanisms Are Involved in the Cardiac Pathology Modulation Mediated by Fenofibrate in an Experimental Model of Chagas Heart Disease.

Authors:  Jimena Rada; Martín Donato; Federico N Penas; Catalina Alba Soto; Ágata C Cevey; Azul V Pieralisi; Ricardo Gelpi; Gerardo A Mirkin; Nora B Goren
Journal:  Front Immunol       Date:  2020-09-24       Impact factor: 7.561

Review 3.  Shared neuroimmune and oxidative pathways underpinning Chagas disease and major depressive disorder.

Authors:  Eduardo Duarte-Silva; Michael Maes; Danielle Macedo; Wilson Savino; Christina Alves Peixoto
Journal:  Transl Psychiatry       Date:  2020-12-02       Impact factor: 6.222

Review 4.  Regulatory T Cells in Chronic Heart Failure.

Authors:  Yuzhi Lu; Ni Xia; Xiang Cheng
Journal:  Front Immunol       Date:  2021-09-22       Impact factor: 7.561

5.  Vasoactive intestinal peptide degradation might influence Interleukin-17 expression in cardiac chagasic patients.

Authors:  Francielle Beltrão Pereira; Walderez O Dutra; Kenneth J Gollob; Edna Afonso Reis; Ana Laura Grossi de Oliveira; Manoel Otávio da Costa Rocha; Cristiane Alves da Silva Menezes
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2018-10-22       Impact factor: 1.846

6.  Genetic polymorphisms of IL17A associated with Chagas disease: results from a meta-analysis in Latin American populations.

Authors:  Mariana Strauss; Miriam Palma-Vega; Desiré Casares-Marfil; Pau Bosch-Nicolau; María Silvina Lo Presti; Israel Molina; Clara Isabel González; Javier Martín; Marialbert Acosta-Herrera
Journal:  Sci Rep       Date:  2020-03-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.